
==== Front
Clin Hematol Int
Clin Hematol Int
3084
Clinical Hematology International
2590-0048
SAABRON PRESS Website: Clinical Hematology International

37752989
87755
10.46989/001c.87755
Research Articles
Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States
Wu Cindy Writing – original draft Writing – review & editing 1
Dongarwar Deepa Data curation Formal Analysis Methodology Software Writing – review & editing 2
Al Hadidi Samer Conceptualization Supervision Writing – original draft Writing – review & editing 3
1 Baylor College of Medicine, Department of Internal Medicine, Houston, TX, USA
2 McGovern School of Medicine, The University of Texas at Houston, Houston, TX, USA
3 Myeloma Center, Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences, Little Rock, AR, USA
a Corresponding author. Tel.: +1 501-526-6990, fax: +1 501-320-7861, e-mail: salhadidi@uams.edu
8 9 2023
2023
5 4 Moving Ahead Anew 511
23 4 2023
31 5 2023
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma (MM) with a poor prognosis. Prior studies have shown that racial disparities affect MM patients in various ways, which may affect patients’ outcomes. In this study, we aimed to investigate racial differences in hospitalization outcomes for PCL using Nationwide Inpatient Sample data. Overall, hospitalization rates for PCL tended to decrease over the past decade. Among hospitalized patients with a primary diagnosis of PCL, there was no statistically significant association between race/ethnicity and hospitalization rates, between NH-White patients and NH-Black patients (OR 1.94; 95%CI 0.3-3.54, p 0.95), and Hispanic patients (OR 0.47; 95% CI 0.05-4.23, p 0.5). Additionally, there was no significant association between race/ethnicity and inpatient mortality. The overall lower incidence of PCL, more significant disease burden, and poor prognosis across all groups may contribute to our findings. With increasing evidence that PCL is cytogenetically distinct from MM, more investigation into biological and sociodemographic factors that affect healthcare utilization and treatment outcomes should be carried out.

African American
Black persons
disparity
multiple myeloma
plasma cell leukemia
None.
==== Body
pmcIntroduction

Plasma cell leukemia (PCL) is a rare subtype of multiple myeloma (MM) with a poor prognosis. While primary PCL was traditionally classified as “de novo” and presenting in patients without a previous diagnosis of MM,1 recent updates by the International Myeloma Working Group have now defined primary PCL by the presence of ≥ 5% circulating plasma cells in the peripheral blood in patients diagnosed with symptomatic MM, based on evidence that patients in this category had similar adverse outcomes with previously defined PCL (≥ 20% circulating plasma cells in peripheral blood).2 Racial disparities have previously been described for MM regarding disease prevalence, treatment outcomes, and mortality. Non-Hispanic Black and Hispanic American patients have a higher incidence of MM, as well as a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS), and Black patients tend to be diagnosed with both MM and MGUS at younger ages, with a previous study showing that Black patients have a 4-year earlier age of onset of MM compared to White patients.3,4 Additionally, in the National Health and Nutritional Examination Survey (NHANES) III, the highest disparity prevalence of MGUS between Black and White patients was seen in the 40-49 age group.5 A previous study also showed that Black patients have a higher prevalence of MM-related hospitalizations than non-Hispanic White patients and Hispanic patients had higher MM-related in-hospital mortality.6 Despite this, non-Hispanic Black and Hispanic patients continue to have a lower rate of enrollment in clinical trials utilizing chimeric antigen receptor T-cell therapy (CART-T) and other novel treatment agents.7,8 Disparities in treatment outcomes and mortality for MM are likely related to socioeconomic and genomic factors4 However, limited data exists for racial/ethnic differences in patients with PCL. We aimed to investigate ethnic/racial differences in hospitalization outcomes for PCL.

Materials and Methods

All data were derived from the 2010-2019 Nationwide Inpatient Sample (NIS), the largest all-payer hospitalization database from the Healthcare Cost and Utilization Project (HCUP). It captures hospital discharge data from the 48 US states and the District of Columbia, covering approximately a fifth of all US hospitalizations, excluding rehabilitation hospitals. International Classification of Disease Clinical Modification (ICD-CM) billing codes from the ninth revision (ICD-9-CM, from 2010 to the third quarter of 2015) and tenth revision (ICD-10-CM, from the fourth quarter of 2015 to 2019) were utilized to identify medical diagnoses and procedures. Socio-demographics provided in the data set included age, sex (male, female), race/ethnicity (Hispanic, Non-Hispanic (NH) Black, NH-White, NH-Other, or missing), primary hospital payer (Medicare, Medicaid, private insurance, self-pay, other), median zip code income quartile, disposition (routine, transfer, died, discharged against medical advice [DAMA] and other), hospital bed size (small, medium, large), hospital location and teaching status (rural, urban non-teaching, urban teaching), and geographic location within the United States (Northeast, South, Midwest, South).

All hospitalizations for patients 18 years or older adults with a discharge diagnosis of plasma cell leukemia as a primary or secondary diagnosis were included. The ICD-9-CM codes used for PCL were 203.1.x, whereas ICD-10-CM codes were C90.1x. Descriptive statistics were used to describe our cohort and to estimate prevalence per 100,000 hospitalizations by age, sex, race/ethnicity, disposition, zip code income quartile, primary payer, hospital region, hospital bed, hospital location, and teaching status, in the overall study population and in those with plasma cell leukemia. Bivariate statistical significance was assessed using Pearson’s chi-squared test. Joinpoint regression was used to analyze temporal trends for plasma cell leukemia from 2010-2019, stratified by race and ethnicity.

Average Annual Percentage Change (AAPC) and 95% confidence intervals were used to represent the rate of change in hospitalizations. Survey logistic regression models were built to assess the association between sociodemographic factors and plasma cell leukemia hospitalizations. In each model, we adjusted for the following covariates: age, sex, race/ethnicity, zip code income quartile, primary payer, hospital region, hospital bed size, and teaching status. For all regression models, the reference categories were set as male (sex), young age (18-39 for this study), NH-White (for race/ethnicity), lowest income quartile, private insurance payer, routine disposition, Northeast hospital region, small bed size, rural non-teaching location. All analyses were conducted using R (version 3∙6∙1), RStudio (Version 1∙2∙5001), or join point Regression Program, version 4.7.0.0 (National Cancer Institute). All tests of statistical significance were two-tailed with alpha set at 5%. Given that the data is publicly available, the study was considered exempt by the Institution Review Board at the University of Arkansas for Medical Sciences.

Results

Between 2010 and 2019, there were 14303 hospitalizations for patients with a primary diagnosis of PCL within the NIS database. Of this cohort, 53.6% were male. Most patients (83%) were between the ages of 40 and 79, with 6.8% ranging from 18-39 years and 10.2% at 80 years or older. The racial/ethnic distribution of this cohort includes 7.8% Hispanic, 22.2% NH-Black, 59.4% Non-Hispanic (NH) White, 4.6% NH-Other, and 5.9% with missing demographic information for race/ethnicity. Additional demographic characteristics are summarized in Table 1.

179917 Table 1. Demographic characteristics of patients with plasma cell leukemia

	Total	Plasma cell leukemia	Prevalence per 100,000 hospitalizations	p-value	
	N=304480139	%=100	N=14303	%=100			
Gender						<0.01	
Male	126276359	41.47%	7669	53.62%	6.0731875		
Female	178096256	58.49%	6629	46.35%	3.7221445		
Missing	107524	0.04%	─	─	─		
Age						<0.01	
18-39 years	74009571	24.31%	973	6.80%	1.3146948		
40-59 years	75799239	24.89%	4804	33.59%	6.3377945		
60-79 years	103746143	34.07%	7061	49.37%	6.8060362		
80+ years	50925186	16.73%	1465	10.24%	2.8767691		
Race/Ethnicity					<0.01	
NH-White	195552023	64.22%	8495	59.39%	4.3441126		
NH-Black	43501544	14.29%	3179	22.23%	7.3077866		
Hispanic	31118963	10.22%	1122	7.84%	3.6055186		
NH-Others	17724049	5.82%	662	4.63%	3.7350382		
Missing	16583559	5.45%	844	5.90%	5.089378		
Disposition					<0.01	
Routine	197456813	64.85%	6905	48.28%	3.4969672		
Transfer	55405931	18.20%	3157	22.07%	5.6979459		
Died	6661290	2.19%	1484	10.38%	22.277967		
DAMA	4125114	1.35%	75	0.52%	1.8181316		
Other	40639779	13.35%	2676	18.71%	6.5846815		
Missing	191211	0.06%	─	─	─		
Zip code Income quartile					<0.01	
Lowest quartile	89832445	29.50%	3508	24.53%	3.9050479		
Second quartile	77223124	25.36%	3449	24.11%	4.4662788		
Third quartile	71316441	23.42%	3589	25.09%	5.0325001		
Highest quartile	59779208	19.63%	3467	24.24%	5.7996754		
Missing	6328919	2.08%	288	2.01%	4.5505401		
Primary Payer					<0.01	
Medicare	142155872	46.69%	6372	44.55%	4.4824037		
Medicaid	52296258	17.18%	1629	11.39%	3.1149456		
Private Insurance	84605886	27.79%	5284	36.94%	6.2454284		
Self-Pay	24860100	8.16%	973	6.80%	3.9139022		
Other	562023	0.18%	45	0.31%	8.0067898		
Hospital Region					<0.01	
Northeast	58223641	19.12%	2802	19.59%	4.8124781		
Midwest	68791079	22.59%	3120	21.81%	4.5354718		
South	118974593	39.07%	5474	38.27%	4.6009823		
West	58490825	19.21%	2906	20.32%	4.9683006		
Hospital Bed Size					<0.01	
Small	52146784	17.13%	1573	11.00%	3.0164852		
Medium	83884697	27.55%	2595	18.14%	3.0935321		
Large	167672304	55.07%	10099	70.61%	6.0230579		
Missing	776354	0.25%	36	0.25%	4.6370599		
Hospital Location and Teaching Status				<0.01	
Rural	31330118	10.29%	683	4.78%	2.1800109		
Urban non-teaching	92357695	30.33%	2387	16.69%	2.5845166		
Urban teaching	180015971	59.12%	11196	78.28%	6.2194482		
Missing	776354	0.25%	36	0.25%	4.6370599		

Over this 10-year period, there was a tendency towards lower hospitalization rates across the entire cohort, with an AAPC of -1.6 in each ethnic/racial category, as shown in Figure 1.

180127 Figure 1. Trends in plasma cell leukemia hospitalizations by race/ethnicity - 2010-2019

Among hospitalized patients with a primary diagnosis of PCL, there was no statistically significant association between race/ethnicity and hospitalization rates, between NH-White and, Hispanic (OR 0.47; 95% CI 0.05-4.23, p 0.5), NH-Black (OR 1.94; 95%CI 0.3-3.54, p 0.95), and NH-Others (OR 1.67, CI 0.47-5.89, p 0.42). Additionally, there was no significant association between gender and hospitalization rates (OR 1.52; 95% CI 0.67-3.42, p 0.32). No significant association was seen between age and hospitalization rates between the 18-39 years age group and 40-59 years (OR 3.78; CI 0.77-18.52, p 0.1), 60-79 years (OR 2.97; CI 0.65-13.49, p 0.16), and 80+ years (OR 1.22; CI 0.2-7.29, p 0.83). In this cohort, hospitalization rates were not significantly associated with death (OR 1.85; CI 0.22-15.41, p 0.57). Other factors examined include zip code income quartile, hospital region, hospital location and teaching status, hospital bed size, and primary payer/insurance status, none of which had a significant association with PCL hospitalizations, as listed in Table 2.

179918 Table 2. Factors associated with plasma cell leukemia hospitalizations

	OR (95% CI)	p-values	
Gender			
Male	reference	
Female	1.52(0.67-3.42)	0.32	
Age			
18-39 years	reference	
40-59 years	3.78(0.77-18.52)	0.1	
60-79 years	2.97(0.65-13.49)	0.16	
80+ years	1.22(0.2-7.29)	0.83	
Race/Ethnicity			
NH-White	reference	
NH-Black	1.04(0.3-3.54)	0.95	
Hispanic	0.47(0.05-4.23)	0.5	
NH-Others	1.67(0.47-5.89)	0.42	
Disposition			
Routine	reference	
Transfer	1.17(0.45-3.05)	0.75	
Died	1.85(0.22-15.41)	0.57	
DAMA	─	─	
Other	1.79(0.71-4.51)	0.22	
Missing			
Zip code Income quartile			
Lowest quartile	reference	
Second quartile	1.06(0.28-4.01)	0.93	
Third quartile	1.36(0.42-4.45)	0.61	
Highest quartile	1.77(0.53-5.88)	0.35	
Primary Payer			
Medicare	reference	
Medicaid	0.42(0.1-1.81)	0.24	
Private Insurance	0.82(0.38-1.77)	0.62	
Self-Pay	─	─	
Hospital Region			
Northeast	reference	
Midwest	0.46(0.14-1.44)	0.18	
South	0.62(0.24-1.64)	0.34	
West	0.53(0.17-1.71)	0.29	
Hospital Bed Size			
Small	reference	
Medium	1.51(0.28-8.16)	0.63	
Large	4.31(0.99-18.77)	0.05	
Hospital Location and Teaching Status			
Rural	reference	
Urban non-teaching	0.86(0.09-7.97)	0.9	
Urban teaching	3.32(0.43-25.68)	0.25	

Discussion

Frequent and prolonged hospitalizations continue to represent a significant burden to individual patients regarding quality of life and on healthcare systems financially. It has been well-established that racial/ethnic disparities in hospitalization rates exist for various diseases, including multiple myeloma.6,9 Currently, limited data exist on the relationship between race/ethnicity and hospitalization rates in plasma cell leukemia. However, prior studies have demonstrated no significant differences for race in overall survival (OS) or causes of death for PCL.10 Overall, the rate of hospitalizations for PCL tended to decrease over the past decade across all groups, possibly owing to changes in the standard of care to more outpatient-based regimens and overall better outcomes for patients with MM.1

In our study, no significant associations between hospitalization rates in patients with PCL were seen for either race/ethnicity or other sociodemographic factors, suggesting the possibility that the same factors driving increased hospitalization rates in MM may not be present to the same degree in PCL. In addition, hospitalization rates in PCL did not correlate with mortality within this cohort. The overall lower incidence of PCL, more significant disease burden, and poor prognosis across all groups may contribute to these findings.6,10 This is supported by a recent study using the Surveillance Epidemiology and End Results (SEER) database, which demonstrated that PCL had a higher mortality rate within 6 months compared to MM, lower median OS, and in contrast to MM, neither age at diagnosis nor race was associated with prognosis in PCL.11 It has been increasingly clear that PCL has distinct biology from MM. For example, there are cytogenetic differences in PCL compared with MM, such as a higher prevalence of 17p deletions, hypodiploidy, and translocation t(14;16), as well as clinical features such as higher incidence of cytopenias, elevated lactate dehydrogenase (LDH), and extramedullary involvement.12,13 It is currently unclear whether there is a relationship between race/ethnicity and these molecular and clinical differences in PCL specifically.

Our analysis has some limitations. The use of the NIS database includes the fact that NIS does not identify or track individual patients, and thus does not differentiate between first-time versus recurrent hospitalizations, and also does not capture observation stays. Our data correspond to hospitalizations, not individual patients, and one patient can be hospitalized several times in different situations. NIS identifies diseases based on ICD codes and may not fully reflect diagnostic accuracy.14 It is essential to acknowledge that the diagnostic criteria of PCL have varied and may remain variable over time. Moreover, some patients with PCL may die outside of the hospital, and this type of death could vary across racial populations, which may have affected our results.

Conclusions

This study found no significant difference between racial groups in hospitalizations and/or hospitalization-related mortality for patients with PCL. With increasing evidence that PCL is cytogenetically distinct from MM,15 more investigation into biological and sociodemographic factors that affect healthcare utilization and treatment outcomes should be carried out.

Abbreviations

MM: multiple myeloma; PCL: plasma cell leukemia; ICD-CM: International Classification of Disease Clinical Modification; NIS: national inpatient sample; LDH: lactate dehydrogenase; SEER: Surveillance Epidemiology and End Results; OS: overall survival; OR: odds ratio; CI: confidence interval; NH: non-Hispanic; AAPC: Average Annual Percentage Change; CAR-T: chimeric antigen receptor T cell; NHANES: National Health and Nutritional Examination Survey; MGUS: monoclonal gammopathy of undetermined significance.

Ethics approval and consent to participate

Given that the data is publicly available, the Institution Review Board at the University of Arkansas for Medical Sciences considered the study exempt.

Consent for publication

We give the Publisher permission to publish the Work.

Availability of data and material

Data used in this study are publicly available.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

CRediT - Authors’ Contribution

Writing – original draft: Cindy Wu (Equal), Samer Al Hadidi (Equal). Writing – review & editing: Cindy Wu (Equal), Deepa Dongarwar (Equal), Samer Al Hadidi (Equal). Data curation: Deepa Dongarwar (Lead). Formal Analysis: Deepa Dongarwar (Lead). Methodology: Deepa Dongarwar (Lead). Software: Deepa Dongarwar (Lead). Conceptualization: Samer Al Hadidi (Lead). Supervision: Samer Al Hadidi (Lead).

Acknowledgments

None.
==== Refs
Plasma Cell Leukemia: Definition, Presentation, and Treatment Current Oncology Reports Gundesen Michael Tveden Lund Thomas Moeller Hanne E. H. Abildgaard Niels 1 2019
21 1 8 1523-3790 10.1007/s11912-019-0754-x 10.1007/s11912-019-0754-x 30689121
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage Blood Cancer Journal Fernández de Larrea Carlos Kyle Robert Rosiñol Laura Paiva Bruno Engelhardt Monika Usmani Saad Caers Jo Gonsalves Wilson Schjesvold Fredrik Merlini Giampaolo Lentzch Suzanne Ocio Enrique Garderet Laurent Moreau Philippe Sonneveld Pieter Badros Ashraf Gahrton Gösta Goldschmidt Hartmut Tuchman Sascha Einsele Hermann Durie Brian Wirk Baldeep Musto Pellegrino Hayden Patrick Kaiser Martin Miguel Jesús San Bladé Joan Rajkumar S. Vincent Mateos Maria Victoria 2 12 2021
11 12 192 2044-5385 10.1038/s41408-021-00587-0 10.1038/s41408-021-00587-0 34857730
Dissecting racial disparities in multiple myeloma Blood Cancer Journal Marinac Catherine R. Ghobrial Irene M. Birmann Brenda M. Soiffer Jenny Rebbeck Timothy R. 17 2 2020
10 2 19 2044-5385 10.1038/s41408-020-0284-7 10.1038/s41408-020-0284-7 32066732
Racial disparities in incidence and outcome in multiple myeloma: a population-based study Blood Waxman Adam J. Mink Pamela J. Devesa Susan S. Anderson William F. Weiss Brendan M. Kristinsson Sigurdur Y. McGlynn Katherine A. Landgren Ola 16 12 2010
116 25 5501 5506 0006-4971 10.1182/blood-2010-07-298760 10.1182/blood-2010-07-298760 20823456
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey Blood Cancer Journal Landgren O Graubard B I Kumar S Kyle R A Katzmann J A Murata K Costello R Dispenzieri A Caporaso N Mailankody S Korde N Hultcrantz M Therneau T M Larson D R Cerhan J R Rajkumar S V 20 10 2017
7 10 e618 2044-5385 10.1038/bcj.2017.97 10.1038/bcj.2017.97 29053158
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study Leukemia & Lymphoma Al Hadidi Samer Dongarwar Deepa Salihu Hamisu M. Kamble Rammurti T. Lulla Premal Hill LaQuisa C. Carrum George Ramos Carlos A. Heslop Helen E. Usmani Saad Z. 18 7 2021
62 13 3256 3263 1042-8194 10.1080/10428194.2021.1953013 10.1080/10428194.2021.1953013 34278937
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma JAMA Network Open Alqazaqi Raghad Schinke Carolina Thanendrarajan Sharmilan Zangari Maurizio Shaughnessy John Jr Zhan Fenghuang Tricot Guido van Rhee Frits Al Hadidi Samer 26 8 2022
5 8 e2228877 2574-3805 10.1001/jamanetworkopen.2022.28877 10.1001/jamanetworkopen.2022.28877 36018590
Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions JCO Oncology Practice Awidi Muhammad Al Hadidi Samer 5 2021
17 5 265 271 2688-1527 10.1200/op.21.00001 10.1200/op.21.00001 33974816
Trends of hospitalization for multiple myeloma patients: insights from the national inpatient sample database. Journal of Clinical Oncology Vakiti Anusha Patel Bhavisha Jonnalagadda Anil Alhaj Moustafa Muhamad Stingo Facundo Mewawalla Prerna Shenoy Aarthi G. 20 5 2018
36 15_suppl e20015 e20015 0732-183X 10.1200/jco.2018.36.15_suppl.e20015 10.1200/jco.2018.36.15_suppl.e20015
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents Cancer Mina Roberto Joseph Nisha S. Kaufman Jonathan L. Gupta Vikas A. Heffner Leonard T. Hofmeister Craig C. Boise Lawrence H. Dhodapkar Madhav V. Gleason Charise Nooka Ajay K. Lonial Sagar 2019
125 3 416 423 0008-543X 10.1002/cncr.31718 10.1002/cncr.31718 30332496
Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database Medicine Ge Xiaoyan Meng Weihan Wang Wenbo Ma Honglin Zhao Siqi Cui Kai 22 7 2022
101 29 e29578 1536-5964 10.1097/md.0000000000029578 10.1097/md.0000000000029578 35866755
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis Blood Gonsalves Wilson I. Rajkumar S. Vincent Go Ronald S. Dispenzieri Angela Gupta Vinay Singh Preet P. Buadi Francis K. Lacy Martha Q. Kapoor Prashant Dingli David Lust John A. Zeldenrust Steven R. Hayman Suzanne R. Kyle Robert A. Gertz Morie A. Kumar Shaji K. 7 8 2014
124 6 907 912 0006-4971 10.1182/blood-2014-03-565051 10.1182/blood-2014-03-565051 24957143
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns Blood Cancer Journal Schinke Carolina Boyle Eileen M. Ashby Cody Wang Yan Lyzogubov Valeriy Wardell Christopher Qu Pingping Hoering Antje Deshpande Shayu Ryan Katie Thanendrarajan Sharmilan Mohan Meera Yarlagadda Naveen Khan Maliha Choudhury Samrat Roy Zangari Maurizio van Rhee Frits Davies Faith Barlogie Bart Morgan Gareth Walker Brian A. 19 6 2020
10 6 70 2044-5385 10.1038/s41408-020-0336-z 10.1038/s41408-020-0336-z 32555163
Overview of the national (nationwide) inpatient sample (NIS) Healthcare Cost and Utilization Project 2018
2023-3-14
The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells Biomedicines Papadhimitriou Stefanos I. Terpos Evangelos Liapis Konstantinos Pavlidis Dimitrios Marinakis Theodoros Kastritis Efstathios Dimopoulos Meletios-Athanasios Tsitsilonis Ourania E. Kostopoulos Ioannis V. 19 1 2022
10 2 209 2227-9059 10.3390/biomedicines10020209 10.3390/biomedicines10020209 35203419
